Q & A from the margin of the binder.

What is GHK-Cu and where does it come from?

GHK-Cu is a tripeptide-copper complex. Three amino acids — glycine, histidine, lysine — wrap around a single copper(II) ion, with three nitrogen atoms from the peptide donating to the metal ^[1]. It was first isolated from human plasma in 1973 as a factor that restored protein synthesis in aged liver tissue, and was originally called Liver Cell Growth Factor before the structure was characterized ^[5].

The molecule is endogenous. Human plasma carries GHK at around 200 ng/mL in young adults, falling to roughly 80 ng/mL by the seventh decade of life ^[5][14]. In cosmetic regulation it is listed under the INCI name Copper Tripeptide-1 ^[18]. The CAS number is 49557-75-7 and the molecular weight is 340.39 Da.

What is the difference between GHK and GHK-Cu?

GHK is the free tripeptide. GHK-Cu is the same tripeptide bound to a copper(II) ion in a 1:1 ratio. Most of the research literature treats the copper-bound complex as the biologically active form for tissue repair and matrix remodeling, while a few effects — notably the acute anxiolytic-like behavior in rats — work with the free peptide alone ^[13][16].

The two forms behave differently in solution. Free GHK is more susceptible to proteolytic degradation; the copper complex is more stable in vivo. In slightly acidic solution the 1:1 Cu:peptide complex is the form the field considers most stable ^[16].

How does GHK-Cu actually affect gene expression?

In cultured human dermal fibroblasts at nanomolar concentrations, GHK-Cu shifts expression of an estimated 4,192 protein-coding genes — about 31.2 percent of the genome — by 50 percent or more, with 59 percent upregulated and 41 percent downregulated ^[5]. The strongest fingerprint is on extracellular matrix remodeling, antioxidant defense, and the resolution of cellular senescence.

Mechanistically, GHK-Cu engages integrin-beta1 on cell surfaces, activates PI3K/Akt signaling, upregulates the Nrf2/Keap1 antioxidant axis, suppresses NF-kB p65 and p38 MAPK, binds SIRT1 (the colitis paper docked it at GLU-230 and ASN-226 with a binding energy of -8.75 kcal/mol), and rebalances MMP-9 to TIMP-1 ratios ^[3][4]. The breadth of the transcriptomic effect is what makes GHK-Cu interesting to bioinformatics researchers; whether all of those predicted changes hold up downstream in vivo is still being worked out.

Does GHK-Cu cross into the brain or affect neurons?

A 2024 paper in Metallomics showed that GHK rescued mouse BV2 microglia, primary CNS neurons, astrocytes, and macrophages from copper(II)- and zinc(II)-induced cell death in vitro, and almost completely abolished cuproptosis-associated DLAT protein aggregation in macrophages exposed to 500 microM Cu2+ ^[9]. The paper also documented resolubilization of preformed metal-protein aggregates.

A separate behavioral thread in Wistar rats showed increased open-arm exploration in the elevated plus maze within 12 minutes of 0.5 microg/kg intraperitoneal GHK, plus roughly 5-fold reductions in inter-male aggression ^[13]. That study is suggestive of a CNS effect after systemic administration, although blood-brain barrier passage has not been comprehensively characterized.

In a rat sciatic nerve transection model, GHK bonded to a collagen prosthesis increased Schwann cell proliferation and upregulated NGF, NT-3, and NT-4 — peripheral nervous system data, but consistent with neurotrophic activity ^[12].

What does the 2024 fibrosis research say about GHK-Cu?

He, Mazzola, and Ladiges (2024) reported that in aged mouse lung fibroblasts at 24 to 26 months, GHK reduced p21 and p53 expression, increased the stemness markers p63 and PCNA, and selectively eliminated excess myofibroblasts through apoptosis ^[3]. The effect required integrin-beta1 signaling at the cell surface. Functionally, the cells restored migration, contraction, and a more youthful gene-expression signature.

This reframes GHK-Cu in the literature from a purely wound-healing peptide to a candidate anti-senescence agent in pulmonary fibrosis specifically. The case still rests on cell-culture and ex-vivo work; large in-vivo trials in mammalian models of established idiopathic pulmonary fibrosis are not yet on the file.

Is there evidence GHK-Cu helps wound healing?

The wound-healing literature is the largest single thread in the GHK-Cu file. In an STZ-induced diabetic rat wound model, a GHK-loaded collagen film accelerated closure and produced roughly 9-fold higher collagen deposition than untreated controls ^[15]. In 2025, a composite hydrogel of egg-white, konjac glucomannan, and GHK-Cu closed S. aureus-infected mouse wounds by more than 95 percent at day 12 versus 65 percent in controls ^[7].

The vehicle matters. Combining GHK-Cu with low-molecular-weight hyaluronic acid at a 1:9 ratio multiplied collagen IV mRNA expression 25.4-fold in human dermal fibroblasts and 2.03-fold in ex-vivo skin ^[8]. GHK-AgNP conjugates have achieved 96 percent closure at day 11 in S. aureus-infected mice with an MIC of 8 microg/mL against E. coli and S. aureus ^[20].

Most of these are rodent studies. Topical human wound and cosmetic studies are smaller but consistent — including the 2024 McGill ultrasound study reporting a 28 percent average increase in dermal echogenic density in 21 subjects over 12 weeks ^[17].

What concentrations are used in GHK-Cu research?

In cell culture, mechanistic studies typically use 1 to 100 nanomolar GHK-Cu, with bell-shaped potency around 10 nM ^[5][8][21]. Neuroprotection-against-acute-metal-stress studies use much higher concentrations — 5 to 10 mM against 125 to 500 microM Cu2+ or Zn2+ ^[9].

In rodent systemic studies, doses range from 0.2 to 20 microg/g/day intraperitoneal in chronic dosing models ^[2], and 0.5 microg/kg for acute behavioral effects ^[13]. Oral gavage at 20 mg/kg has been used in mouse colitis ^[4]. Topical cosmetic formulations use 0.05 percent to 2 percent w/w of Copper Tripeptide-1 ^[18][19].

These are research concentrations and routes. They are not human dose recommendations.

What is GHK-Cu's half-life and how stable is it?

Free GHK has a short plasma half-life on the order of minutes due to plasma peptidases. The copper-bound complex is markedly more stable in vivo ^[16]. Tissue retention after topical or microneedle delivery extends to hours-to-days depending on vehicle ^[22].

In solution the complex is photo- and oxidation-sensitive. Dry lyophilized powder is robust under refrigeration. The most stable and biologically active form is a 1:1 Cu:peptide complex in slightly acidic solution ^[16]. Glutathione reduces Cu(II)-GHK via a characterized Cu(II)-thiolate intermediate without releasing free copper, which is why the complex has a low pro-oxidant profile under physiological conditions.

Is GHK-Cu FDA approved?

GHK-Cu is not approved by the FDA as a drug for any human indication ^[19]. Topical Copper Tripeptide-1 is permitted as a cosmetic ingredient under cosmetic regulation, which is a separate and lighter-touch regulatory category from drug approval ^[18][19].

Compounded injectable GHK-Cu was removed from FDA compounding Category 2 in April 2026 after the original 503A bulks-list nominations were withdrawn. The legal status of compounded injectable GHK-Cu is currently in flux pending Pharmacy Compounding Advisory Committee review ^[19]. The compounding question is regulatory and procedural, not a statement about the chemistry of the molecule itself.

Is GHK-Cu on the WADA prohibited list?

GHK-Cu is not currently named on the WADA Prohibited List. Athletes should re-check the annually updated list before any use of any peptide compound, because some peptides have moved categories without notice in past cycles.

WADA status is also distinct from FDA status — a compound can be permitted for testing competition while remaining unapproved as a drug, and vice versa. The two regulatory systems answer different questions.

Why do GHK-Cu plasma levels decline with age?

The mechanism of the age-related decline is not fully resolved in the literature. The observation itself — approximately 200 ng/mL in the third decade of life dropping to roughly 80 ng/mL by the seventh — is well documented across multiple studies ^[5][14]. Hypotheses include reduced protein turnover with age, declining release from precursor proteins, and increased clearance by peptidases.

What the observation does not establish is that restoring plasma GHK to youthful levels produces measurable clinical benefit in humans. That is a separate empirical question, and the data we have are mostly topical and small-scale.

Has GHK-Cu been studied in cancer cell lines?

Yes. In MCF7 breast cancer and PC3 prostate cancer cell lines, GHK-Cu at 1 to 10 nM modulated 84 genes associated with DNA repair, downregulated well-defined cancer-enhancer signatures, and produced coordinated changes in caspases, p63 (a p53 family tumor suppressor), and growth-regulatory factors ^[11]. Molecular docking studies have characterized GHK interactions with estrogen receptor alpha — hydrogen bonding with Glu-353, van der Waals interactions with Arg-394 and His-524 — with binding profiles comparable to small-molecule oncology agents ^[10].

This is cell-line work and computational docking, not in vivo oncology data. Connectivity Map analyses have identified GHK as a top reverser of disease signatures for metastatic colon cancer, with reversal of approximately 70 percent of an overexpressed-gene signature ^[5]. The clinical bridge from these signatures to any human cancer therapy remains unbuilt.

What scaffolds and dressings are used to deliver GHK-Cu?

The scaffold and dressing literature is creative and growing. Examples in the file: polydopamine-coated 3D-printed silk scaffolds for vascularized bone regeneration in a rat calvarial defect ^[6]; composite hydrogels of egg-white, konjac glucomannan, and GHK-Cu for full-thickness infected wounds ^[7]; collagen films loaded with GHK-Cu for diabetic rat wounds ^[15]; GHK-AgNP conjugates against S. aureus-infected mouse wounds ^[20]; and polymeric microneedle pre-treatment for transdermal delivery through ex-vivo human skin ^[22].

Each vehicle changes what the peptide does. The Mohammed microneedle paper specifically established that the rate-limiting barrier for topical GHK-Cu is physical, not biochemical — once the stratum corneum is bypassed, permeation reaches 134 +/- 12 nmol over 9 hours ^[22].

Where is the GHK-Cu evidence still thin?

Three places. First, there are no large randomized controlled trials of systemic GHK-Cu in humans. The strongest human data are small topical cosmetic studies. Second, the Connectivity Map case rests on bioinformatic prediction; not every predicted gene-level effect has been validated downstream in vivo. Third, human pharmacokinetics across the various systemic routes the rodent literature has explored are not systematically characterized.

The online discourse about systemic injectable GHK-Cu for hair, joints, or cognition routinely outruns the published evidence, which is overwhelmingly topical or preclinical ^[19]. Holding those two facts together — strong preclinical signal plus thin human systemic data — is the honest summary.